S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and GOP rush to complete debt ceiling deal, shore up support to prevent default
66,000% upside on tiny biotech? (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
66,000% upside on tiny biotech? (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:TNGX

Tango Therapeutics (TNGX) Stock Forecast, Price & News

$2.99
+0.07 (+2.40%)
(As of 05/26/2023 ET)
Compare
Today's Range
$2.90
$3.15
50-Day Range
$2.92
$4.70
52-Week Range
$2.88
$8.56
Volume
130,632 shs
Average Volume
138,487 shs
Market Capitalization
$264.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

Tango Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
435.1% Upside
$16.00 Price Target
Short Interest
Healthy
3.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Tango Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.40) to ($1.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

400th out of 1,012 stocks

Pharmaceutical Preparations Industry

182nd out of 495 stocks


TNGX stock logo

About Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Tango Therapeutics (TNGX) Receives a Buy from H.C. Wainwright
TNGX Tango Therapeutics, Inc.
See More Headlines
Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TNGX Company Calendar

Last Earnings
5/09/2023
Today
5/28/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNGX
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+435.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-108,180,000.00
Net Margins
-446.26%
Pretax Margin
-446.04%

Debt

Sales & Book Value

Annual Sales
$24.86 million
Book Value
$2.57 per share

Miscellaneous

Free Float
85,136,000
Market Cap
$264.35 million
Optionable
Not Optionable
Beta
1.62

Key Executives

  • Dr. Barbara L. Weber M.D. (Age 66)
    Pres, CEO & Director
    Comp: $796.2k
  • Ms. Daniella Beckman CPA (Age 43)
    Chief Financial Officer
    Comp: $545.82k
  • Dr. Alan Huang Ph.D. (Age 49)
    Chief Scientific Officer
    Comp: $566.54k
  • Dr. Alan Ashworth FRS (Age 61)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Dr. Levi Garraway M.D.
    Ph.D., Founder
  • Dr. William G. Kaelin Jr. (Age 64)
    M.D., Founder & Member of Scientific Advisory Board
  • Dr. Timothy K. Lu M.D. (Age 41)
    Ph.D., Founder
  • Dr. Antoni Ribas M.D. (Age 55)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Douglas J. Barry Esq. (Age 52)
    J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Mr. John C. Ross M.S.
    VP of HR













TNGX Stock - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings
or view top-rated stocks.

What is Tango Therapeutics' stock price forecast for 2023?

1 brokers have issued 1 year price targets for Tango Therapeutics' shares. Their TNGX share price forecasts range from $11.00 to $21.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 435.1% from the stock's current price.
View analysts price targets for TNGX
or view top-rated stocks among Wall Street analysts.

How have TNGX shares performed in 2023?

Tango Therapeutics' stock was trading at $7.25 at the beginning of 2023. Since then, TNGX stock has decreased by 58.8% and is now trading at $2.99.
View the best growth stocks for 2023 here
.

Are investors shorting Tango Therapeutics?

Tango Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 1,820,000 shares, a drop of 18.0% from the April 30th total of 2,220,000 shares. Based on an average daily trading volume, of 166,100 shares, the short-interest ratio is currently 11.0 days. Currently, 3.6% of the shares of the company are short sold.
View Tango Therapeutics' Short Interest
.

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our TNGX earnings forecast
.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The company had revenue of $5.77 million for the quarter, compared to analysts' expectations of $6.70 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 42.34% and a negative net margin of 446.26%.

What ETFs hold Tango Therapeutics' stock?

ETFs with the largest weight of Tango Therapeutics (NASDAQ:TNGX) stock in their portfolio include Invesco DWA SmallCap Momentum ETF (DWAS), Invesco Nasdaq Biotechnology ETF (IBBQ).

What is Tango Therapeutics' stock symbol?

Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX."

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (10.78%), BlackRock Inc. (4.00%), Geode Capital Management LLC (1.00%), State Street Corp (0.93%), Bank of New York Mellon Corp (0.16%) and Swiss National Bank (0.12%).
View institutional ownership trends
.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tango Therapeutics' stock price today?

One share of TNGX stock can currently be purchased for approximately $2.99.

How much money does Tango Therapeutics make?

Tango Therapeutics (NASDAQ:TNGX) has a market capitalization of $264.35 million and generates $24.86 million in revenue each year. The company earns $-108,180,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis.

How can I contact Tango Therapeutics?

Tango Therapeutics' mailing address is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.tangotx.com. The company can be reached via phone at 857-320-4900.

This page (NASDAQ:TNGX) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -